Publications and Awards

Publications

Mycobacteria

• Lyu J, Narum DE, Baldwin SL, Larsen SE, Bai X, Griffith DE, Dartois V, Naidoo T, Steyn AJC, Coler RN and Chan ED. Understanding the development of tuberculous granulomas: insights into host protection and pathogenesis, a review in humans and animals. Front. Immunol. 15:1427559. doi: 10.3389/fimmu.2024.1427559
• Painter H, Larsen SE, Williams BD, Abdelaal HFM, Baldwin SL, Fletcher HA, Fiore-Gartland A, Coler RN. Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependent. mSphere 0:e00864-24. doi.org/10.1128/msphere.00864-24
• Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humans. Provisionally Accepted - doi: 10.3389/fimmu.2024.1441944. Andrew Fiore-Gartland, Himangi Srivastava, Aaron Seese, Tracey Day, Adam Penn-Nicholson, Angelique Kany Kany Luabeya, Nelita Du Plessis, Andre G Loxton, Linda-Gail Bekker, Andreas Diacon, Gerhard Walzl, Zachary K Sagawa, Steven G Reed, Thomas Scriba, Mark Hatherill and Rhea Coler
• The Chosen Few: Mycobacterium tuberculosis isolates for IMPAc-TB. Provisionally Accepted - doi: 10.3389/fimmu.2024.1427510. Sasha E Larsen, Hazem F.M. Abdelaal, Courtney R Plumlee, Sara Cohen, Ho D Kim, Qingyun Liu, Matthew H Harband, Bryan J Berube, Susan L. Baldwin, Sarah Fortune, Kevin B Urdahl and Rhea N Coler
• Antibodies as key mediators of protection against Mycobacterium tuberculosis. Published - https://doi.org/10.3389/fimmu.2024.1430955. Qixin Wang, Deepika Nag, Susan L. Baldwin, Rhea Coler, Ryan P McNamara
• Choi YH, Kang YA, Park KJ, Choi JC, Cho KG, Ko DY, Ahn JH, Lee B, Ahn E, Woo YJ, Jung K, Kim NY, Reese VA, Larsen SE, Baldwin SL, Reed SG, Coler RN, Lee H, Cho SN. Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Infect Dis Ther. 2023 Jun;12(6):1605-1624. doi: 10.1007/s40121-023-00806-0. Epub 2023 May 11. PMID: 37166567; PMCID: PMC10173211.
• Larsen SE, Baldwin SL, Coler RN. Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis? Int J Infect Dis. 2023 May;130 Suppl 1:S47-S51. doi: 10.1016/j.ijid.2023.03.035. Epub 2023 Mar 23.PMID: 36963657; PMCID: PMC10033141.
• Larsen SE, Erasmus JH, Reese VA, Pecor T, Archer J, Kandahar A, Hsu FC, Nicholes K, Reed SG, Baldwin SL, Coler RN. An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis. Vaccines (Basel). 2023 Jan 5;11(1):130. doi: 10.3390/vaccines11010130. PMID: 36679975; PMCID: PMC9862644.
• Baldwin SL, Reese VA, Larsen SE, Pecor T, Brown BP, Granger B, Podell BK, Fox CB, Reed SG and Coler RN (2022) Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations. Front. Microbiol. 13:935444. doi: 10.3389/fmicb.2022.935444
• Abdelaal HFM, Chan ED, Young L, Baldwin SL, and Coler RN, Mycobacterium abscessus: It's Complex. Microorganisms. 2022 Jul 19;10(7):1454. doi: 10.3390/microorganisms10071454. PMID: 35889173; PMCID: PMC9316637.
• Larsen SE, Reese VA, Pecor T, Berube BJ, Cooper SK, Brewer G, Ordway D, Henao-Tamayo M, Podell BK, Baldwin SL, Coler RN. Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models. Sci Rep. 2021 Apr 27;11(1):9040. doi: 10.1038/s41598-021-88291-8. PMID: 33907221; PMCID: PMC8079704.
• Day T, Penn-Nicholson A, Luabeya A, Fiore-Gartland A, Du Plessis N, Loxton AG, Vergara J, Rolf T, Reid T, Toefy A, Shenje J, Geldenhuys H, Tameris M, Mabwe S, Bilek N, Bekker LG, Diacon A, Walzl G, Ashman J, Frevol A, Sagawa ZK, Reed SG, Scriba T, Hatherill M, Coler RN. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respir Med. 2021 Apr;9(4):373-386. doi: 10.1016/S2213-2600(20)30319-2. Epub 2020 Dec 8. Erratum in: Lancet Respir Med. 2021 Jul;9(7):e62. PMID: 33306991.
• Baldwin SL, Reese VA, Larsen SE, Beebe E, Guderian J, Orr MT, Fox CB, Reed SG, Coler RN. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model. PLoS One. 2021 Mar 11;16(3):e0247990. doi: 10.1371/journal.pone.0247990. PMID: 33705411; PMCID: PMC7951850.
• Carrigy NB, Larsen SE, Reese V, Pecor T, Harrison M, Kuehl PJ, Hatfull GF, Sauvageau D, Baldwin SL, Finlay WH, Coler RN, Vehring R. Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29. Antimicrob Agents Chemother. 2019 Sep 9;63(12):e00871-19. doi: 10.1128/AAC.00871-19. Epub 2019 Sep 16. PMID: 31527037; PMCID: PMC6879268.
• Baldwin SL, Larsen SE, Ordway D, Cassell G, Coler RN. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl Trop Dis. 2019 Feb 14;13(2):e0007083. doi: 10.1371/journal.pntd.0007083. PMID: 30763316; PMCID: PMC6375572.
• Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, Jayashankar L, Walker R, Snowden MA, Evans T, Ginsberg A, Reed SG, Team T-S. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines. 2018 Sep 4;3:34. doi: 10.1038/s41541-018-0057-5. PMID: 30210819; PMCID: PMC6123489.

SARS-CoV-2

• Cardemil CV, Cao Y, Posavad CM, Badell ML, Bunge K, Mulligan MJ, Parameswaran L, Olson-Chen C, Novak RM, Brady RC, DeFranco E, Gerber JS, Pasetti M, Shriver M, Coler R, Berube B, Suthar MS, Moreno A, Gao F, Richardson BA, Beigi R, Brown E, Neuzil KM, Munoz FM; MOMI-Vax Study Group. Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants. Pediatrics. 2024 Mar 1;153(3):e2023064252. doi: 10.1542/peds.2023-064252. PMID: 38332733; PMCID: PMC10904887
• Protective interplay: Mycobacterium tuberculosis diminishes SARS-CoV-2 severity through innate immune priming. Williams, B. D., Ferede, D., Abdelaal, H. F. M., Berube, B. J., Podell, B. K., Larsen, S. E., Baldwin, S. L., & Coler, R. N., Frontiers in Immunology, 2024, PMID: 38966641
• Munoz FM, Posavad CM, Richardson BA, Badell ML, Bunge KE, Mulligan MJ, Parameswaran L, Kelly CW, Olson-Chen C, Novak RM, Brady RC, Pasetti MF, Defranco EA, Gerber JS, Shriver MC, Suthar MS, Coler RN, Berube BJ, Kim SH, Piper JM, Miller AM, Cardemil CV, Neuzil KM, Beigi RH. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn. DMID 21-0004 Study Group. Vaccine. 2023 Aug 14;41(36):5296-5303. doi:10.1016/j.vaccine.2023.06.032. Epub 2023 Jun 13.PMID: 374518783.
• Larsen SE, Berube BJ, Pecor T, Cross E, Brown BP, Williams B, Johnson E, Qu P, Carter L, Wrenn S, Kepl E, Sydeman C, King NP, Baldwin SL, Coler RN. Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. bioRxiv. 2021 Jul 2;. doi: 10.1101/2021.07.02.450915. PubMed PMID: 34230930; PubMed Central PMCID: PMC8259906.
• Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020. Epub 2020/07/15. doi: 10.1056/NEJMoa2022483. PubMed PMID: 32663912; PMCID: PMC7377258.

Other

•  Van Hoeven N, Wiley S, Gage E, Fiore-Gartland A, Granger B, Gray S, Fox C, Clements DE, Parks DE, Winram S, Stinchcomb DT, Reed SG, Coler RN. A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen. NPJ Vaccines. 2018;3:39. doi: 10.1038/s41541-018-0077-1. PubMed PMID: 30302281.PMC6158298.
• Baldwin SL, Hsu FC, Van Hoeven N, Gage E, Granger B, Guderian JA, Larsen SE, Lorenzo EC, Haynes L, Reed SG, Coler RN. Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection. Front Immunol. 2018 Feb 19;9:295. PMID: 29515589; PMCID: PMC5826078.

Travel Awards